M. Salgo

发表

Evaluation of pharmacokinetics, safety, tolerance, and activity of combination of zalcitabine and zidovudine in stable, zidovudine-treated pediatric patients with human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 190 Team.

L. Mofenson, D. Schoenfeld, M. Fowler, 1997, The Journal of infectious diseases.

Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.

J. Montaner, D. Kuritzkes, S. Walmsley, 2003, The New England journal of medicine.

Population Pharmacokinetics and Exposure‐response Relationship of Enfuvirtide in Treatment‐experienced Human Immunodeficiency Virus Type 1—infected Patients

D. Mould, I. Patel, K. Nieforth, 2005, Clinical pharmacology and therapeutics.

opulation pharmacokinetics and xposure-response relationship of nfuvirtide in treatment-experienced uman immunodeficiency virus ype 1 – infected patients

K. Nieforth, Xiaoping Zhang, N. Buss, 2005 .

Safety of Enfuvirtide in Combination With an Optimized Background of Antiretrovirals in Treatment-Experienced HIV-1-Infected Adults Over 48 Weeks

J. Montaner, B. Clotet, D. Kuritzkes, 2005, Journal of acquired immune deficiency syndromes.

The SPICE Study: 48‐Week Activity of Combinations of Saquinavir Soft Gelatin and Nelfinavir With and Without Nucleoside Analogues

M. Opravil, N. Clumeck, A. Pozniak, 2000, Journal of acquired immune deficiency syndromes.

Durable Efficacy of Enfuvirtide Over 48 Weeks in Heavily Treatment-Experienced HIV-1-Infected Patients in the T-20 Versus Optimized Background Regimen Only 1 and 2 Clinical Trials

J. Montaner, B. Clotet, D. Kuritzkes, 2005, Journal of acquired immune deficiency syndromes.

Randomised, Multicentre Phase III Study of Saquinavir plus Zidovudine plus Zalcitabine in Previously Untreated or Minimally Pretreated HIV-Infected Patients

D. Hawkins, H. Stellbrink, D. Cooper, 2000 .

Week-12 response to therapy as a predictor of week 24, 48, and 96 outcome in patients receiving the HIV fusion inhibitor enfuvirtide in the T-20 versus Optimized Regimen Only (TORO) trials.

C. Katlama, M. Saag, F. Raffi, 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates

Lei Jin, T. Matthews, M. Greenberg, 2004, AIDS.

Impact of Human Immunodeficiency Virus Type 1 gp41 Amino Acid Substitutions Selected during Enfuvirtide Treatment on gp41 Binding and Antiviral Potency of Enfuvirtide In Vitro

J. Erickson, D. Lambert, T. Matthews, 2005, Journal of Virology.

Pharmacokinetics, Pharmacodynamics and Drug Interaction Potential of Enfuvirtide

I. Patel, K. Nieforth, Xiaoping Zhang, 2005, Clinical pharmacokinetics.

Enfuvirtide (T-20) cross-reactive glycoprotein 41 antibody does not impair the efficacy or safety of enfuvirtide.

B. Clotet, C. Katlama, S. Walmsley, 2003, The Journal of infectious diseases.

Thorough QT/QTc Study of Ritonavir‐Boosted Saquinavir Following Multiple‐Dose Administration of Therapeutic and Supratherapeutic Doses in Healthy Participants

Xiaoping Zhang, S. Kolis, P. Jordan, 2012, Journal of clinical pharmacology.

Population Pharmacokinetics of Enfuvirtide in HIV‐1‐Infected Pediatric Patients Over 48 Weeks of Treatment

I. Patel, Xiaoping Zhang, A. Dorr, 2007, Journal of clinical pharmacology.

Safety and tolerability of zalcitabine (ddC) in patients with AIDS or advanced AIDS-related complex in the European expanded access programme.

G. Moyle, M. Salgo, R. Harris, 1996, International journal of antimicrobial agents.

Zalcitabine Compared with Zidovudine in Patients with Advanced HIV-1 Infection Who Received Previous Zidovudine Therapy

M. Fischl, S. Follansbee, S. Remick, 1993, Annals of Internal Medicine.

A randomized, controlled study evaluating an induction treatment strategy in which enfuvirtide was added to an oral, highly active antiretroviral therapy regimen in treatment-experienced patients: the INTENSE study.

B. Clotet, J. Schapiro, J. Gatell, 2008, The Journal of antimicrobial chemotherapy.

Switching from a Toxicity-Causing Antiretroviral to Enfuvirtide in Patients with HIV: The SWITCH TOX Study

S. Staszewski, A. Streinu-Cercel, S. Rugină, 2008, HIV clinical trials.

Enfuvirtide Does Not Require Dose Adjustment in Patients With Chronic Kidney Failure: Results of a Pharmacokinetic Study of Enfuvirtide in HIV-1-Infected Patients With Impaired Kidney Function

P. Tebas, I. Patel, L. Rowell, 2008, Journal of acquired immune deficiency syndromes.

Seeking ethical designs for HIV clinical trials in treatment-experienced patients: an industry perspective.

D. Mayers, D. Hall, N. Buss, 2006, AIDS research and human retroviruses.

Multiple Polyexponentials and Quasipolynomials as Empirical Nonlinear Regression Models: A Case Study with HIV Viral Load Data

L. Huson, J. Chung, M. Salgo, 2006, Journal of biopharmaceutical statistics.

Prognostic Staging of Extensively Pretreated Patients with Advanced HIV-1 Disease

J. Montaner, M. Salgo, Jain Chung, 2005, HIV clinical trials.

Missing Data Imputation in Two Phase III Trials Treating HIV1 Infection

L W Huson, J Chung, M Salgo, 2007, Journal of biopharmaceutical statistics.

Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia.

Christine Katlama, Joep Lange, Adriano Lazzarin, 2003, The New England journal of medicine.

Ritonavir and saquinavir combination therapy for the treatment of HIV infection.

R Rode, M Salgo, D. Ho, 1999, AIDS.

Efficacy and Safety of 48 Weeks of Enfuvirtide 180 mg Once-Daily Dosing Versus 90 mg Twice-Daily Dosing in HIV-Infected Patients

N. Graham, S. Walmsley, L. Rowell, 2008, HIV clinical trials.

Comparative trial of two dosages of zalcitabine in zidovudine-experienced children with advanced human immunodeficiency virus disease. Pediatric AIDS Clinical Trials Group.

S. Spector, J. Oleske, S. Blanchard, 1997, The Pediatric Infectious Disease Journal.

Pharmacokinetic Interaction Study of Ritonavir-Boosted Saquinavir in Combination with Rifabutin in Healthy Subjects

Xiaoping Zhang, L. Rowell, E. Zwanziger, 2010, Antimicrobial Agents and Chemotherapy.

Improved Survival and Reduced Clinical Progression in HIV-Infected Patients with Advanced Disease Treated with Saquinavir plus Zalcitabine

R. Haubrich, D. Richman, H. Burger, 1998, Antiviral Therapy.

Human immunodeficiency virus type 1 RNA level and CD4 count as prognostic markers and surrogate end points: A meta-analysis

S. Hammer, D. Katzenstein, R. Schooley, 2000 .

Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes

Michael Greenberg, Jain Chung, D. Bolognesi, 2004, Nature Reviews Drug Discovery.

Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: A randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients

T. Butler, K. Kudsk, W. Lesslauer, 2001, Critical care medicine.

HIV fusion and its inhibition in antiretroviral therapy

M. Greenberg, N. Cammack, M. Salgo, 2004, Reviews in medical virology.

Safety, tolerability, and plasma pharmacokinetics of high-strength formulations of enfuvirtide (T-20) in treatment-experienced HIV-1-infected patients.

J. Kilby, I. Patel, J. Lalezari, 2004, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

The SPICE study: 48-week activity of combinations of saquinavir soft gelatin and nelfinavir with and without nucleoside analogues. Study of Protease Inhibitor Combinations in Europe.

M. Johnson, M. Opravil, N. Clumeck, 2000 .

Characterization of envelope glycoprotein gp41 genotype and phenotypic susceptibility to enfuvirtide at baseline and on treatment in the phase III clinical trials TORO-1 and TORO-2.

M Salgo, T. Kirkland, T. Matthews, 2006, AIDS research and human retroviruses.

Investigators’ Experience With Expedited Safety Reports Prior to the FDA’s Final IND Safety Reporting Rule

S. Ellenberg, L. Szczech, J. Kramer, 2014, Therapeutic innovation & regulatory science.

TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals.

J. Montaner, B. Clotet, D. Kuritzkes, 2007, AIDS patient care and STDs.

Guillain-Barré syndrome associated with immune reconstitution.

G. Drusano, T. Kinchelow, M. Salgo, 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes.

D. Bolognesi, T. Matthews, M. Greenberg, 2004 .

Adherence to enfuvirtide and its impact on treatment efficacy.

J. Rockstroh, E. Dejesus, L. Rowell, 2008, AIDS research and human retroviruses.

Viral decay dynamics in HIV-infected patients receiving ritonavir-boosted saquinavir and efavirenz with or without enfuvirtide: a randomized, controlled trial (HIV-NAT 012).

A. Perelson, K. Ruxrungtham, D. Cooper, 2006, The Journal of infectious diseases.

A Controlled Phase Ii Trial Assessing Three Doses of Enfuvirtide (T-20) in Combination with Abacavir, Amprenavir, Ritonavir and Efavirenz in Non-Nucleoside Reverse Transcriptase Inhibitor-Naive HIV-Infected Adults

Gary Richmond, Edwin DeJesus, Richard Haubrich, 2002, Antiviral therapy.